- Home
- GMAB vs ILMN Comparison
GMAB vs ILMN Comparison
Compare GMAB & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- ILMN
- Stock Information
- Founded
- GMAB 1999
- ILMN 1998
- Country
- GMAB Denmark
- ILMN United States
- Employees
- GMAB N/A
- ILMN N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- ILMN Medical Specialities
- Sector
- GMAB Health Care
- ILMN Health Care
- Exchange
- GMAB Nasdaq
- ILMN Nasdaq
- Market Cap
- GMAB 17.4B
- ILMN 15.3B
- IPO Year
- GMAB N/A
- ILMN 2000
- Fundamental
- Price
- GMAB $30.54
- ILMN $122.51
- Analyst Decision
- GMAB Strong Buy
- ILMN Hold
- Analyst Count
- GMAB 6
- ILMN 15
- Target Price
- GMAB $40.40
- ILMN $114.93
- AVG Volume (30 Days)
- GMAB 2.6M
- ILMN 2.0M
- Earning Date
- GMAB 11-06-2025
- ILMN 10-30-2025
- Dividend Yield
- GMAB N/A
- ILMN N/A
- EPS Growth
- GMAB 132.41
- ILMN N/A
- EPS
- GMAB 25.10
- ILMN 4.46
- Revenue
- GMAB $3,845,670,022.00
- ILMN $4,288,000,000.00
- Revenue This Year
- GMAB $24.92
- ILMN N/A
- Revenue Next Year
- GMAB $15.97
- ILMN $2.22
- P/E Ratio
- GMAB $1.21
- ILMN $27.49
- Revenue Growth
- GMAB 29.57
- ILMN N/A
- 52 Week Low
- GMAB $17.24
- ILMN $68.70
- 52 Week High
- GMAB $33.65
- ILMN $153.06
- Technical
- Relative Strength Index (RSI)
- GMAB 57.89
- ILMN 67.60
- Support Level
- GMAB $28.08
- ILMN $118.50
- Resistance Level
- GMAB $29.35
- ILMN $125.50
- Average True Range (ATR)
- GMAB 0.69
- ILMN 4.97
- MACD
- GMAB 0.02
- ILMN 1.64
- Stochastic Oscillator
- GMAB 93.41
- ILMN 89.05
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.